Citius Pharmaceuticals Inc (NASDAQ: CTXR) stock trades $2.20 Citius Pharmaceuticals Inc (NASDAQ: CTXR) stock closed at $2.20 (up 1.85%) on July 9, 2021. It pared 12% in the past month. The stock currently has a market capitalization of $283.14 million and a 52-week range of $0.78-$4.56. FuelCell Energy Inc (NASDAQ: […]
Tag: Citius Pharmaceuticals Inc (NASDAQ: CTXR)
Citius Pharmaceuticals Inc (NASDAQ: CTXR) Milestones Update
Citius Pharmaceuticals Inc (NASDAQ: CTXR), a vital player in developing of critical care products, provides an update on upcoming milestones and business highlights for the six-month period ending June 30, 2021. Upcoming Milestones: Citus Pharmaceuticals reported that DMC (Data Monitoring Committee) stated the continuation of the Phase 3 Mino-Lok trial […]
Citius Pharmaceuticals Inc (NASDAQ: CTXR) Announces Optimistic Endorsement by Autonomous Statistics Observing Group
Citius Pharmaceuticals Inc (NASDAQ: CTXR) announced subsequent an unblinded statistics appraisal of security and effectiveness. The Autonomous Statistics Observing Group for the Mino-Lok® Phase 3 Fundamental Dominance Pilot has suggested continuing with the trial as intended. Committee found no security anxieties The Autonomous Statistics Observing Group did not recognize any […]
Where Will Citius Pharmaceuticals Inc (NASDAQ: CTXR) Head From Here?
Citius Pharmaceuticals Inc (NASDAQ: CTXR) closed at $3.69 on Friday, up 2.5%. Its yearly range is $0.78 – $3.87. Inching closer to its all-time high, the biopharmaceutical company has a market capitalization of 499.90M USD. The company, which aims to create care products for cancer patients, has recently appointed Dr. […]